XBI - SPDR S&P Biotech ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
76.79
-1.08 (-1.39%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close77.87
Open77.16
Bid0.00 x 900
Ask0.00 x 4000
Day's Range76.44 - 78.14
52 Week Range73.97 - 101.55
Volume4,533,277
Avg. Volume5,936,056
Net Assets4.38B
NAV81.57
PE Ratio (TTM)N/A
Yield0.28%
YTD Return-3.60%
Beta (3Y Monthly)2.12
Expense Ratio (net)0.35%
Inception Date2006-01-31
Trade prices are not sourced from all markets
  • Traders bet there's more pain ahead for biotech
    CNBC Videos2 months ago

    Traders bet there's more pain ahead for biotech

    Biotech ETF (XBI) is on pace for its worst month since January 2016, and traders believe the pain may continue.

  • TheStreet.com7 days ago

    3 Profitable Small Biotech Names to Consider

    Exelixis Inc., ANI Pharmaceuticals and Supernus Pharmaceuticals should not need to raise more capital in the foreseeable future.

  • TheStreet.com10 days ago

    A Way to Exploit Algorithm-Induced Market Swings When Trading Biotech Issues

    One trigger was the arrest in Canada for extradition to the United States of the well-connected CFO of China telecom champion Huawei Technologies Co. because of that company's alleged evasion of U.S. sanctions on Iran. Contributing mightily to the recent volatility in the stock market is the rise of algorithmic trading -- basically, computer programs that trade instantly on the latest headlines. A respected fund manager on CNBC the other day stated that 80% of the trading volume in any given day is driven by these automated trading engines.

  • MarketWatch13 days ago

    Revance Therapeutics reaches licensing agreement with Fosun Pharmaceutical over botox formulation RT002

    Shares of Revance Therapeutics Inc. were up 1.9% in premarket trade Tuesday after the company announced it had entered an agreement with Shanghai Fosun Pharmaceutical Industrial Development Co. to give Fosun exclusive rights to develop and commercialize Revance's botulinum toxin formulation RT002 in mainland China, Hong Kong and Macau. Under the licensing agreement, Revance will receive an upfront payment of $30 million and is eligible to receive up to an additional $230.5 million in future development and sales milestone payments, as well as royalties on future net sales. Shares of Revance have fallen 42% in the year to date, while the iShares Nasdaq Biotechnology exchange traded fund has gained 3.3%. The SPDR S&P Biotech ETF, which includes smaller biotech companies, has fallen 0.3%, and the S&P 500 has advanced 4.4%.

  • Why Clovis Oncology Stock Rose 48% in November
    Market Realist13 days ago

    Why Clovis Oncology Stock Rose 48% in November

    On December 3, Clovis Oncology stock closed at $19.08, which represents ~10.87% growth from its close of $17.21 on November 30. Clovis Oncology’s stock price grew from $11.63 at the close of business on October 31 to $17.21 at the close of the market on November 30, which reflects ~48% growth in November.

  • Chinese biotech stocks hit by a double whammy, which means it’s time to buy
    MarketWatch17 days ago

    Chinese biotech stocks hit by a double whammy, which means it’s time to buy

    The decline in biotech stocks is more about investors fleeing a high-beta group in a risk-off environment.

  • Why Acadia Pharmaceuticals Stock Rose 20.8% Yesterday
    Market Realist18 days ago

    Why Acadia Pharmaceuticals Stock Rose 20.8% Yesterday

    On November 28, Acadia Pharmaceuticals (ACAD) stock closed at $20.53, which represents a ~20.76% rise from its close of $17.00 on November 27. On November 27, Acadia Pharmaceuticals announced a price of $17.00 per share for an underwritten public offering of 16,176,471 shares of its common stock. Acadia Pharmaceuticals’ net revenue in the first nine months of the year amounted to $164.2 million compared to $81.3 million in the same period last year.

  • These 2 shocks will jolt stocks higher — and 15 smart ways to prepare for that move
    MarketWatch19 days ago

    These 2 shocks will jolt stocks higher — and 15 smart ways to prepare for that move

    Investor sentiment has now fallen prey to the stock-market equivalent of cardiac arrest. Sentiment is now so dead that it suggests the next leg of the stock market is up, in the contrarian sense. This ratio has spiked to levels frequently followed by rallies, says Doug Ramsey, chief investment officer of The Leuthold Group.

  • TheStreet.com24 days ago

    There Are Few Good Setups, but I'm Watching Support Levels

    The problem today is that the market negative has been consistently negative for a while and even when there is a relief bounce, like we had on Wednesday, the strength is being used as an opportunity for reduction of long positions rather than a sign that a bottom may be forming. Overall breadth is running negative, with around 3200 gainers to 3600 decliners, and there are over 250 names hitting new 12-month lows. -- are still under pressure and the DJIA is at a recent closing lows.

  • 7 Biotech ETFs to Consider for 2019
    InvestorPlace27 days ago

    7 Biotech ETFs to Consider for 2019

  • Drug prices may be rising, but you can buy biotech stocks at rock-bottom levels
    MarketWatchlast month

    Drug prices may be rising, but you can buy biotech stocks at rock-bottom levels

    Consider Gilead Sciences (GILD) and Celgene (CELG) for example. At recent prices of $70 and $75, they traded at market values that aren’t too far above the value of their operating businesses, according to discounted cash flow analysis by Jefferies biotech analyst Michael Yee and his team. Then add if they fall back to their “free pipeline” stock prices.

  • Benzingalast month

    The Time Could Be Right For This Biotech ETF

    Biotechnology stocks and exchange traded funds have been slumping since last week's midterm elections and that could be an ominous sign. Ongoing weakness for the equal-weight S&P Biotechnology Select Industry Index benefits the Direxion Daily S&P Biotech Bear 3X Shares (NYSE: LABD). LABD, one of the most heavily traded leveraged biotechnology ETFs, aims to deliver triple the daily inverse returns of the S&P Biotechnology Select Industry Index.

  • How Has Cara Therapeutics’ 2018 Performance Shaken Out?
    Market Realistlast month

    How Has Cara Therapeutics’ 2018 Performance Shaken Out?

    Cara Therapeutics (CARA) is a clinical-stage biotechnology company developing new chemical entities for managing pain and pruritus. Cara Therapeutics reported EPS of -$0.52 on revenue of $2.87 million in the second quarter.

  • Benzingalast month

    The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

    Earnings and U.S. midterm polls continued to positively influence biotech stocks, with the sector notching gains for the second straight week. These are some of the upcoming week's catalysts that could ...

  • Portola Pharmaceuticals Stock Rose after Its Q3 2018 Results
    Market Realistlast month

    Portola Pharmaceuticals Stock Rose after Its Q3 2018 Results

    On November 8, after Portola Pharmaceuticals released its third-quarter financial results, the stock price rose 21.41%. On November 8, Portola Pharmaceuticals stock price closed at $23.14, which was ~21.41% growth from its previous close of $19.06. On November 7, Portola Pharmaceuticals stock price closed at $19.06, which was ~2.80% growth from its previous close of $18.54. On November 7, the company hit its 52-week low of $18.18.

  • ETF Trendslast month

    Biotech ETFs Hoping This Post-Election Trend Doesn’t Repeat

    Stocks rallied Wednesday, a day after one of the most contentious midterm elections in U.S. history. In Tuesday's midterm elections, Democrats emerged with control of the House while Republicans maintained control of the Senate. Among the winning exchange traded funds Wednesday were biotechnology funds, including the SPDR S&P Biotech ETF (XBI) , which takes an equal-weight approach to the biotech space.

  • TheStreet.comlast month

    Jim Cramer: Why the Market Did What It Did Today and What Can Happen Tomorrow

    First, I see most buyers embracing the concept of gridlock from either the House going Democratic or both the House and Senate changing hands. It stands for a return to high growth because of what is expected to be a do nothing Congress that blocks anything President Trump wants. In a do nothing Congress we anniversary the tax cuts that pumped money into the system so that's gone.

  • Benzingalast month

    The Health Care Stocks With A Lot Riding On The Midterm Elections

    Americans and investors have a lot riding on Tuesday’s midterm elections, but the health care industry in particular is hanging in the balance. On Monday, Height Capital Markets named four themes in the ...

  • Benzingalast month

    The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

    Biotech earnings news flow accelerated in last week, with Pfizer Inc. (NYSE: PFE ) and Sanofi SA (NYSE: SNY ) among the noteworthy releases of the week. With the earnings news flow set to continue, these ...

  • How Celgene’s Otezla, Abraxane, and Other Drugs Performed
    Market Realist2 months ago

    How Celgene’s Otezla, Abraxane, and Other Drugs Performed

    Celgene’s (CELG) Otezla reported revenues of $432.0 million in the third quarter, a ~40.3% YoY increase. In the US and international markets, Otezla generated revenues of $348.0 million and $84.0 million, respectively, compared to $250.0 million and $58.0 million in the third quarter of 2017, reflecting ~39.2% and ~44.8% YoY growth. In the third quarter, in the international market, Otezla witnessed ~45.7% YoY operational growth.

  • Trump's Approval Rises Before Midterms: ETFs to Lose/Gain
    Zacks2 months ago

    Trump's Approval Rises Before Midterms: ETFs to Lose/Gain

    Recent improvement in Trump's approval rating puts these ETFs in focus.